Healthcare / BiotechnologyBrussels
$2.72
-0.12 (-4.23%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-32.7M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$189M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-75.5%
↓Gross Margin
72.5%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+231.2%
FCF CAGR
—
FCF margin
-1044.9%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.8M · net income $-41.8M · FCF $-39.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.8M | $3.8M | $229000.00 | $68000.00 | $104000.00 |
| Net Income | $-41.8M | $-41.8M | $-35.7M | $-36.2M | $-32.8M |
| EBITDA | $-37.8M | $-37.8M | $-32.9M | $-34.0M | $-31.3M |
| EPS | — | — | -0.80 | -1.20 | -1.09 |
| Gross Margin | 72.5% | 72.5% | 90.4% | 100.0% | -14122.1% |
| Operating Margin | -1082.4% | -1082.4% | -15223.6% | -52151.5% | -30796.2% |
| Net Margin | -1105.5% | -1105.5% | -15600.4% | -53207.4% | -31511.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.31 | 0.94 | 0.27 |
| Current Ratio | 6.67 | 6.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-39.5M | $-39.5M | $-31.9M | $-32.7M | $-27.1M |
| Returns | |||||
| ROE | -75.5% | -75.5% | -74.3% | -201.8% | -62.3% |
| Valuation | |||||
| P/B | 2.75 | 2.75 | 4.90 | 5.17 | 3.52 |
| Growth & Yield | |||||
| Revenue Growth | 1550.7% | 1550.7% | 236.8% | -34.6% | — |
| EPS Growth | — | — | 33.3% | -10.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.80 → n/d
Residual
-36.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.